Immunotherapy combined with antiangiogenic therapy as third‐ or further‐line therapy for stage IV non‐small cell lung cancer patients with ECOG performance status 2: A retrospective study

• DOI: 10.1002/cam4.7349
• Publication Date: 2024-06-14T06:54:51Z
• Authors: Shuo Li; Ze‐Shun Yu; Hong‐Zhi Liu; Shu‐Jing Li; Ming‐Yue Wang; Fang‐Ling Ning; Li‐Jun Tian
• Keywords: non‐small cell lung cancer; Male; Adult; Lung Neoplasms; Indoles; Reviews; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Carcinoma, Non-Small-Cell Lung; Antineoplastic Combined Chemotherapy Protocols; Humans; RC254-282; Retrospective Studies; Aged; Neoplasm Staging; Aged, 80 and over; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; Middle Aged; Endostatins; Bevacizumab; Eastern Cooperative Oncology Group; antiangiogenic therapy; Quinolines; Quality of Life; Female; immunotherapy; Immunotherapy

AbstractBackgroundPatients with Eastern Cooperative Oncology Group performance status (ECOG PS) 2 probably cannot tolerate chemotherapy or other antitumor therapies. Some studies have reported that immunotherapy combined with antiangiogenic therapy is well‐tolerated and shows good antitumor activity. However, the efficacy of this combination as a later‐line therapy in patients with ECOG PS 2 is unclear. This study evaluated the effectiveness and safety of this combination strategy as third‐ or further‐line therapy in stage IV non‐small cell lung cancer (NSCLC) patients with ECOG PS 2.MethodsIn this retrospective study, patients treated with camrelizumab plus antiangiogenic therapy (bevacizumab, anlotinib, or recombinant human endostatin) were included. Objective response rate (ORR), disease control rate (DCR), progression‐free survival (PFS), overall survival (OS), quality of life (QOL) assessed by ECOG PS, and safety were analyzed.ResultsBetween January 10, 2019, and February 28, 2024, a total of 59 patients were included. The ORR was 35.6% (21/59) and the DCR was 86.4%. With a median follow‐up of 10.5 months (range: 0.7–23.7), the median PFS was 5.5 months (95% confidence interval [CI]: 3.8–7.3) and the median OS was 10.5 months (95% CI: 11.2–13.6). QOL was improved (≥1 reduction in ECOG PS) in 39 patients (66.1%). The most common Grade 3–4 treatment‐related adverse events were hepatic dysfunction (6 [10%]), hypertension (5 [8%]), and hypothyroidism (3 [5%]). There were no treatment‐related deaths.ConclusionsThird‐ or further‐line immunotherapy combined with antiangiogenic therapy is well‐tolerated and shows good antitumor activity in stage IV NSCLC patients with ECOG PS 2. Future large‐scale prospective studies are required to confirm the clinical benefits of this combination therapy.